









Markets
/
Stocks
/
nasdaq-cgem
/

Cullinan Therapeutics Inc

CGEM

6.340USD

+0.410+6.91%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

374.53MMarket Cap

LossP/E TTM



Cullinan Therapeutics Inc

6.340

+0.410+6.91%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite strong stock market performance and technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

83 / 506

Overall Ranking

188 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 11 analysts

Buy

Current Rating

26.333

Target Price

+344.07%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator.

Overvalued

The company’s latest PE is -1.81, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 71.64M shares, decreasing 14.45% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.01M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 5.87, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is average.

Score

Industry at a Glance

Previous score

5.87

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.38

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

6.16

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.69, which is 38.59% below the recent high of -2.34 and -66.01% above the recent low of -2.81.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 83/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.91, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Cullinan Therapeutics Inc is 24.00, with a high of 34.00 and a low of 22.00.

Score

Industry at a Glance

Previous score

8.91

Change

Support & Resistance

No Data

Analyst Rating

Based on 11 analysts

Buy

Current Rating

26.333

Target Price

+344.07%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Cullinan Therapeutics Inc

CGEM

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.38, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 7.54 and the support level at 5.11, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.38

Change

0.32

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.184

Sell

RSI(14)

38.682

Neutral

STOCH(KDJ)(9,3,3)

20.842

Buy

ATR(14)

0.417

Low Volatility

CCI(14)

-90.532

Neutral

Williams %R

76.684

Sell

TRIX(12,20)

-0.767

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

6.288

Buy

MA10

6.519

Sell

MA20

7.077

Sell

MA50

7.489

Sell

MA100

7.784

Sell

MA200

8.819

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 121.39%, representing a quarter-over-quarter decrease of 1.79%. The largest institutional shareholder is The Vanguard, holding a total of 3.01M shares, representing 5.10% of shares outstanding, with 1.39% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

MPM BioImpact LLC

7.65M

BVF Partners L.P.

5.75M

Lynx1 Capital Advisors LLC

3.22M

+155.66%

Deerfield Management Company, L.P.

3.86M

+14.25%

BlackRock Institutional Trust Company, N.A.

3.81M

-2.64%

The Vanguard Group, Inc.

Star Investors

3.03M

+3.53%

Citadel Advisors LLC

2.75M

+2.39%

Blue Owl Capital Holdings LP

2.44M

+2.74%

Franklin Advisers, Inc.

2.20M

+0.84%

Kynam Capital Management LP

2.34M

+86.68%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.12, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -0.09. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.